Accessibility StatementSkip Navigation SAN DIEGO, Sept. 16, 2025 /PRNewswire/ -- Robbins LLPÂ reminds stockholders that a class action was filed on behalf of persons and entities that purchased or otherwise acquired Savara Inc. (NASAQ: SVRA) securities between March 7, 2024 and May 23, 2025. Savara is a clinical-stage biopharmaceutical company focused on rare respiratory diseases. The Company's lead product candidate is MOLBREEVI (also referred to as "molgramostim"), an inhaled granulocyte-macrophage colony ...

LOS ANGELES, Sept. 11, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Savara, Inc., ("Savara" or the "Company") (NASDAQ: SVRA) investors of a class action on behalf of investors that bought securities between March 7, 2024 and May 23, 2025, inclusive (the “Class Period”). Savara investors have until November 7th, 2025 to file a lead plaintiff motion. Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: lesley@portnoylaw.com, to discuss their legal rights, or ...

NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Savara Inc. (“Savara” or the “Company”) (NASDAQ: SVRA) and certain officers.   The class action, filed in the United States District Court for the Eastern District of Pennsylvania, and docketed under 25-cv-05147, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Savara securities between March 7, 2024 and May 23, 2025, ...